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Background and purpose: Morphological brain changes related to hypovitaminosis
D have been poorly studied. In particular, the age-related decrease in vitamin D
concentrations may explain the onset of white matter abnormalities (WMA) in older
adults. Our objectives were (i) to investigate whether there was an association
between serum 25-hydroxyvitamin D (25OHD) concentration and the grade of
WMA in older adults and (ii) to determine whether the location of WMA was asso-
ciated with 25OHD concentration.
Methods: One hundred and thirty-three Caucasian older community-dwellers with
no clinical hydrocephalus (mean 71.6  5.6 years; 43.6% female) received a blood
test and a magnetic resonance imaging scan of the brain. The grades of total, peri-
ventricular and deep WMA were scored using semiquantitative visual rating scales
from T2-weighted ﬂuid-attenuated inversion recovery images. The association of
WMA with as-measured and deseasonalized 25OHD concentrations was evaluated
with the following covariates: age, gender, body mass index, use of anti-vascular
drugs, number of comorbidities, impaired mobility, education level, Mini-Mental
State Examination score, medial temporal lobe atrophy, serum concentrations of
calcium, thyroid-stimulating hormone and vitamin B12, and estimated glomerular
ﬁltration rate.
Results: Both as-measured and deseasonalized serum 25OHD concentrations were
found to be inversely associated with the grade of total WMA (adjusted b = 0.32,
P = 0.027), speciﬁcally with periventricular WMA (adjusted b = 0.15, P = 0.009)
but not with deep WMA (adjusted b = 0.12, P = 0.090). Similarly, participants
with 25OHD concentration <75 nM had on average a 33% higher grade of periven-
tricular WMA than those with 25OHD ≥75 nM (P = 0.024). No diﬀerence in aver-
age grade was found for deep WMA (P = 0.949).
Conclusions: Lower serum 25OHD concentration was associated with higher grade
of WMA, particularly periventricular WMA. These ﬁndings provide a scientiﬁc
basis for vitamin D replacement trials.
Introduction
Hypovitaminosis D is very common in older adults,
with nearly one in two older adults having hypovita-
minosis D [1,2]. Besides its classical function of bone
metabolism regulation, vitamin D has been shown in
the past decade to have multiple biological targets
mediated by its nuclear hormone receptor, the vitamin
D receptor, including brain neurons, astrocytes and
microglia [1–7]. Consistently, experimentation has
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demonstrated that vitamin D is active in the brain
and is able to reverse some age-related brain changes
[8]. Several actions are described, including participa-
tion in neurophysiology through genetic regulation of
neurotransmitters, neurotrophins and dendritic growth
[4,5,9], but also neuroprotective eﬀects based on
antioxidant and anti-inﬂammatory properties
[4,5,8,10]. It even seems that the brain parenchyma
has greater vitality with adequate vitamin D impreg-
nation and is better able to resist ischaemic stress [11].
Aging brain is characterized by a non-speciﬁc
increase in white matter abnormalities (WMA), called
leukoaraiosis [12–14]. WMA are easily visualized on
magnetic resonance imaging (MRI) either in the deep
white matter (D-WMA) or in contact with the lateral
cerebral ventricles (periventricular WMA, P-WMA).
The clinical relevance of both D-WMA and P-WMA
is related to the disruption of cortico-subcortical white
matter tracts that connect important cognitive regions
of the brain [15], making them risk factors associated
with cognitive decline [16].
Morphological brain changes related to low vitamin
D status have been poorly studied [17]. Since epidemio-
logical studies have reported that older adults with
hypovitaminosis D have more frequent and more
severe cognitive disturbances than those with normal
levels [3,18], and based on the experimentally
described neurosteroid properties of vitamin D, it was
hypothesized that the age-related decrease in vitamin
D levels could explain, at least in part, the WMA
observed in older adults. The objectives of the present
study were (i) to investigate whether there was an
association between serum 25-hydroxyvitamin D
(25OHD) concentration and the grade of WMA in
older adults, and (ii) if so to determine whether the
location of the WMA was associated with 25OHD
concentration.
Materials and methods
Participants
Our study involved 133 older community-dwellers
(mean age 71.6  5.6 years; 43.6% female; 100% Cau-
casian) followed in the Memory Clinic of the Univer-
sity Hospital of Angers, France, and recruited in the
Gait and Alzheimer Interactions Tracking (GAIT)
study from November 2009 to July 2011. The GAIT
study is an observational cross-sectional study
designed to examine gait in older community-dwellers
reporting subjective memory complaint. The sampling
and data collection procedures have been described
elsewhere in detail [19]. In summary, subjective mem-
ory complaint was documented using the Subjective
Memory Complaints Questionnaire [20] and the main
exclusion criteria were age below 60 years, Mini-Men-
tal State Examination (MMSE) score <10 [21], inability
to walk independently, a history of stroke, history of
any acute medical illness within the past 3 months,
current delirium, severe depression, and inability to
understand or answer the study questionnaires. For
the present analysis, subjects were excluded when a
diagnosis of clinical hydrocephalus was made based on
the neurological evaluation (triad of gait instability,
cognitive dysfunction and urinary incontinence) [22].
All included study participants received a full medical
examination, consisting of structured questionnaires
and standardized clinical examination, a cerebral MRI
scan and a blood test.
White matter abnormalities
Scan protocol
Imaging of the brain was performed with a 1.5 T
MRI scanner (Magnetom Avanto, Siemens
Medical Solutions, Erlangen, Germany) using a stan-
dard MRI protocol [22] including T1-weighted magne-
tization prepared rapid acquisition gradient echo
axial images (acquisition matrix 256 9 256 9 144,
FOV 240 mm 9 240 mm 9 187 mm, TE/TR/
TI = 4.07 ms/2170 ms/1100 ms), T2-weighted ﬂuid-
attenuated inversionrecovery (FLAIR)axial images (acqui-
sition matrix 256 9 192, FOV 240 mm 9 180 mm, slice
thickness 5 mm, slice gap 0.5 mm, 30 slices, TE/TR/
TI = 122 ms/9000 ms/2500 ms), T2-weighted turbo spin-
echo axial images, and T2*-weighted axial images.
WMA measurements
The grade of WMA was evaluated from the T2-
weighted FLAIR MR images, under the supervision
of two neuroradiologists (TA and IBG), by a single
observer (CA) who was blinded from participants’
clinical information, including age, gender, prior
imaging ﬁndings, comorbidities and cardiovascular
risk factors, amongst others.
The total extent of white matter signal-intensity
abnormality was measured using the semiquantitative
visual rating scale devised by Manolio et al. [23], with
a score ranging from 0 to 9 (worst). The inter-rater
agreement of this scale is fair, with Cohen j = 0.59
[24]. D-WMA and P-WMA were characterized from
the T2-weighted FLAIR images using the semiquanti-
tative visual rating scale devised by Fazekas et al.
[25]. D-WMA were scored on a four-point scale of
increasing severity, according to the following: 0, nor-
mal; 1, punctuate foci; 2, beginning conﬂuence of foci;
3, large conﬂuent areas. P-WMA were scored as fol-
lows: 0, normal; 1, ‘caps’ or pencil-thin lining; 2,
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smooth ‘halo’; 3, irregular periventricular hyperinten-
sities extending into the deep white matter. The
reliability of the Fazekas scale is excellent, with an
intra-operator correlation coeﬃcient of 0.85 [26] and
inter-rater agreement Cohen j = 0.78 [24].
Serum vitamin D assessment
Venous blood was collected from resting participants at
the time of the brain imaging acquisition. Serum
25OHD concentration, an eﬀective indicator of vitamin
D status [1,2], was measured by radioimmunoassay
(DiaSorin Inc., Stillwater, MN, USA) in nanomoles (to
convert to ng/ml, divide by 2.496). With this method,
there is no interference of lipids, which is often
observed in other non-chromatographic assays of
25OHD. The intra- and inter-assay precision was 5.2%
and 11.3% respectively. All measurements were per-
formed locally at the University Hospital of Angers,
France.
Deseasonalized 25OHD concentrations were calcu-
lated by regressing the measured 25OHD concentra-
tions (in nM) on the periodic function:
yt ¼ 0 þ 1sin 2t
365
 
þ 2cos 2t
365
 
;
where yt denotes measured serum 25OHD concentra-
tion, t denotes the day of the year the sample was col-
lected and bj (j = 0, 1, 2) are estimated regression
coeﬃcients. Then the residuals were added to the sea-
sonal average to create a deseasonalized vitamin D
concentration for each individual [27,28]. This pro-
vides a way to adjust for the seasonal variation of
25OHD given that blood samples were collected
throughout the year. ‘January 1’ deseasonalized values
were arbitrarily chosen for analysis [28], although in a
periodic function any date would be expected to be
equally informative (and subject to the same limita-
tions). Given the assumptions and limitations inherent
in deseasonalized analysis, parallel analyses using
as-measured 25OHD values were also performed.
Covariates
The following clinical variables were included as
potential confounders in the statistical models: age,
gender, body mass index (BMI), use of anti-vascular
drugs, number of comorbidities, impaired mobility,
education level and MMSE score. The serum concen-
trations of calcium, thyroid-stimulating hormone and
vitamin B12, estimated glomerular ﬁltration rate, and
medial temporal lobe (MTL) atrophy were also used
as covariates in the analysis.
Assessment of clinical covariates
Clinical covariates were obtained from a physical
examination and a standardized comprehensive geri-
atric assessment. BMI was calculated as weight
divided by height2 (kg/m2). Evaluation of chronic
diseases was based on self-report and health status
questionnaires. Comorbidities were diseases lasting at
least 3 months or running a course with minimal
change, whatever their nature or site. The treatments
usually taken were determined from the primary care
physician’s prescriptions and by questioning the
patient, whatever the dosage schedule or route of
administration, and regardless of the date of com-
mencement. Anti-vascular drugs were deﬁned as anti-
hypertensive (i.e. diuretics, beta-blockers, calcium
antagonists, angiotensin conversion enzyme inhibi-
tors, agonists of angiotensin II receptors or central
antihypertensive agents), anti-diabetic (i.e. insulin or
oral anti-diabetic agents), lipid-lowering (i.e. statins
or ﬁbrates) and anti-platelet drugs (i.e. aspirin, clopi-
dogrel, ticlopidin or dipyridamole). Impaired mobility
was deﬁned by gait velocity slower than 100 cm/s at
usual pace [29] using an electronic portable walkway
with pressure sensor pads connected to a computer
(GAITRite Gold walkway, 972 cm long, active elec-
tronic surface area 792 9 610 cm, with a total of
29 952 pressure sensors, scanning frequency 60 Hz,
software version 3.8; CIR System, Havertown, PA,
USA). Education level was self-reported with a struc-
tured standardized questionnaire. Participants who
did graduate studies were considered to have a
higher level of education compared with those who
did not. Finally, cognitive status was assessed with
the Folstein MMSE score [21].
Assessment of biological covariates
Serum calcium, creatinine, thyroid-stimulating hor-
mone and vitamin B12 were determined using auto-
mated standard laboratory methods at the University
Hospital of Angers, France. Because of the high prev-
alence of hypoalbuminemia in older adults, serum
concentrations of albumin and calcium were used to
correct the calcium value: corrected calcium = uncor-
rected calcium (mM) + ([40  albumin (g/l)] 9 0.02).
Estimated glomerular ﬁltration rate was estimated
using the CockcroftGault formula ([(140 
ageyears) 9 weightkg/creatininelM] 9 1.04 for females
and 9 1.25 for males).
MTL atrophy was characterized from T1-weighted
images using the qualitative ﬁve-point visual scale by
Scheltens et al. [30]. The score ranges from 0 (no atro-
phy) to 4 (severe atrophy) based on the height of the
hippocampal formation and the surrounding cerebro-
spinal ﬂuid spaces. In the analysis, MTL atrophy was
© 2014 The Author(s)
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deﬁned as a score >2 at least on one side (right or
left) [30]. The scans were rated by a single blinded
rater (CA) under the supervision of two neuroradio-
logists (TA and IBG) (intra-rater weighted Cohen
j = 0.68) [31].
Statistical analysis
First, the participants’ characteristics were summa-
rized using means  standard deviations or frequen-
cies and percentages, as appropriate. Secondly, linear
regressions were used to examine the association
between serum 25OHD concentration (independent
variable) and the grade of WMA (dependent vari-
able), whilst adjusting for potential confounders. Sep-
arate analyses were performed to predict total WMA,
D-WMA and P-WMA from deseasonalized and as-
measured 25OHD concentrations. In order to improve
the clinical signiﬁcance of our results, an increase of
25 nM was used to deﬁne a unit of serum 25OHD
change. Finally, D-WMA and P-WMA were com-
pared between participants with serum 25OHD con-
centration <75 nM and those with 25OHD ≥75 nM
using a two-sided Student t test. P values <0.05 were
considered signiﬁcant. All statistics were performed
using SPSS (v20.0; IBM Corporation, Chicago, IL,
USA) and Stata (v12.1; Stata Corporation, College
Station, TX, USA).
Standard protocol approvals, registrations and patient
consents
Subjects participating in the study were included after
having given their written informed consent for
research. The study was conducted in accordance with
the ethical standards set forth in the Helsinki Declara-
tion (1983) and the protocol was approved by the
University of Angers Ethical Review Committee (CPP
Ouest II – 200912).
Results
As indicated in Table 1, the mean as-measured con-
centration of serum 25OHD was 58.6  27.6 nM, and
the mean deseasonalized value of 25OHD was
54.0  27.3 nM. Forty serum assays were performed
in spring, 21 in summer, 50 in autumn and 22 in win-
ter (P < 0.001). Mean grade of total WMA was
2.4  1.8 on the Manolio scale (/9). Mean grade of
D-WMA was 1.3  0.7 on the Fazekas scale (/3), and
mean P-WMA was 1.0  0.9 (/3). Thirty-ﬁve partici-
pants (26.3%) presented with MTL atrophy.
Linear regression showed an inverse association of
deseasonalized 25OHD concentration with the grade of
P-WMA (unadjusted b = 0.13; 95% CI 0.24, 0.02;
P = 0.020), but not with D-WMA (unadjusted
b = 0.03; 95% CI 0.17, 0.11; P = 0.645). After
adjustment for potential confounders, serum 25OHD
concentration was inversely associated with the grade
of total WMA (adjusted b = 0.32; 95% CI 0.60,
0.04; P = 0.027) and P-WMA (adjusted b = 0.15;
95% CI 0.26, 0.04; P = 0.009), but not D-WMA
(adjusted b = 0.12; 95% CI 0.27, 0.02; P = 0.090)
Table 1 Summary of the participants’ characteristics (n = 133)
Characteristics
Cohort (n = 133)
Summary value 95% CI
Demographic measures
Age, years 71.6  5.6 [65–89] 70.7; 72.6
Female
gender, n (%)
58 (43.6) 35.2; 52.0
Body mass
index, kg/m2
25.9  4.0 [16.6–48.2] 25.2; 26.6
Regular use of
anti-vascular
drugsa, n (%)
46 (34.6) 26.5; 42.7
Number of
comorbiditiesb
2.1  1.7 [0–8] 1.8; 2.4
Impaired
mobilityc, n (%)
54 (40.6) 32.4; 48.9
Higher education
leveld, n (%)
36 (27.1) 19.6; 34.7
MMSE score, /30 26.9  3.4 [12–30] 26.3; 27.5
Serum measures
25OHD, nM
As-measured
values
58.6  27.6 [13–189] 53.9; 63.3
Deseasonalized
values
54.0  27.3 [13.3–182.8] 49.4; 58.6
Calciume, mM 2.4  0.1 [2.1–2.7] 2.4; 2.4
Estimated glomerular
ﬁltration rate, ml/min
63.8  30.1 [21.3–343.8] 58.7; 68.9
TSH, mUI/l 1.9  1.1 [0.1–5.9] 1.7; 2.1
Vitamin B12, ng/l 466.1  205.8 [150–1714] 431.1; 501.1
Brain mapping measures
Grade of white matter
abnormalities
Total WMAf, /9 2.4  1.8 [0–9] 2.1; 2.7
Periventricular
WMAg, /3
1.3  0.7 [0–3] 1.2; 1.4
Deep WMAh, /3 1.0  0.9 [0–3] 0.9; 1.2
Medial temporal lobe
atrophyi, n (%)
35 (26.3) 18.8; 33.8
Summary values presented as mean  standard deviation [range]
where applicable. CI, conﬁdence interval; MMSE, Mini-Mental State
Examination; 25OHD, 25-hydroxyvitamin D; TSH, thyroid-stimulat-
ing hormone; WMA, white matter abnormalities. aAntihypertensive,
anti-diabetic, lipid-lowering or anti-platelet drugs; bdiseases lasting
at least 3 months or running a course with minimal change; cusual
gait velocity slower than 100 cm/s; dgraduate studies; ecorrected
value; fManolio scale; gFazekas scale for periventricular white matter
abnormalities; hFazekas scale for deep white matter abnormalities;
iscore on Scheltens scale >2 at least on one side.
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(Table 2). Using as-measured values of serum 25OHD
concentration did not alter the associations with the
grades of total WMA (adjusted b = 0.31; 95% CI
0.59, 0.03; P = 0.032) and P-WMA (adjusted
b = 0.14; 95% CI 0.25, 0.03; P = 0.012). In addi-
tion, MTL atrophy was positively associated with the
grade of total WMA, D-WMA and P-WMA. Increased
calcium concentration was also associated with both
the grade of total WMA and D-WMA (Table 2).
Finally, Fig. 1 shows representative examples of T2-
weighted FLAIR MR axial images in participants with
25OHD < 75 nM and those with 25OHD ≥ 75 nM.
The grade of P-WMA was higher in participants with
25OHD < 75 nM compared with the others, with a
33% diﬀerence (P = 0.024), but there was no diﬀerence
for the grade of D-WMA (P = 0.949).
Discussion
The main ﬁnding of this study performed in French
older community-dwellers is that, irrespective of all
measured potential confounders, serum vitamin D
concentration was independently and inversely associa-
ted with total WMA in older adults. This association
was found to involve speciﬁcally the P-WMA but not
the D-WMA.
Despite accumulating evidence emphasizing the
eﬀects of vitamin D on the brain, particularly with
regard to cognitive function [3,18], there are few stud-
ies on the impact of lower vitamin D levels on brain
morphometry. To the best of our knowledge, only
one observational study has explored the association
of hypovitaminosis D with WMA thus far [32]. Those
authors reported that older community-dwellers from
the Boston area, MA, USA, had a larger volume and
a more severe grade of WMA in the case of serum
25OHD < 25 nM than those with 25OHD > 50 nM.
They also found that people with higher vitamin D
dietary intakes ≥400 IU/day had a smaller volume
and less severe grade of WMA than the others [32].
However, this study did not consider the location of
WMA, a crucial factor that may provide important
information on the implicated mechanisms [12,13,33].
Moreover, the epidemiological approach was only
descriptive in this ﬁrst study, and no regression model
was used to examine the association between serum
25OHD and WMA, which prevented the authors tak-
ing into account confounding factors such as calcium
concentration. Yet, the link reported between hypovi-
taminosis D and WMA may have reﬂected covaria-
tion with this biological component related to both
vitamin D status and vascular risk [34]. Despite these
Table 2 Multiple linear regressions showing the cross-sectional associations between the grades of total, periventricular and deep white matter
abnormalities (dependent variables)a and serum 25-hydroxyvitamin D concentration (independent variable)b,c adjusted for participants’ charac-
teristics (n = 133)
Grade of white matter abnormalitiesa
Total white matter abnormalities
Periventricular white matter
abnormalities
Deep white matter
abnormalities
Adjusted b 95% CI P Adjusted b 95% CI P Adjusted b 95% CI P
Serum 25OHD concentrationb,c 0.32 0.60; 0.04 0.027 0.15 0.26; 0.04 0.009 0.12 0.27; 0.02 0.090
Age 0.05 0.03; 0.12 0.206 0.04 0.01; 0.07 0.013 0.03 0.01; 0.07 0.086
Female gender 0.13 0.77; 0.50 0.676 0.14 0.39; 0.11 0.267 0.09 0.41; 0.23 0.580
Body mass index 0.06 0.02; 0.15 0.144 0.04 0.01; 0.07 0.027 0.02 0.03; 0.06 0.479
Use of anti-vascular drugsd 0.25 0.42; 0.91 0.471 0.04 0.22; 0.30 0.760 0.01 0.32; 0.34 0.958
Number of comorbiditiese 0.12 0.33; 0.09 0.267 0.04 0.12; 0.04 0.329 0.02 0.12; 0.09 0.736
Impaired mobilityf 0.61 1.26; 0.04 0.067 0.13 0.38; 0.13 0.340 0.22 0.55; 0.11 0.195
Higher education levelg 0.43 0.29; 1.15 0.238 0.08 0.21; 0.36 0.598 0.01 0.37; 0.35 0.964
MMSE score 0.09 0.20; 0.03 0.159 0.01 0.04; 0.05 0.885 0.01 0.07; 0.05 0.703
Serum calcium concentrationh 3.93 0.73; 7.12 0.017 1.00 0.26; 2.27 0.119 1.64 0.02; 3.27 0.047
Estimated glomerular ﬁltration
rate
0.01 0.01; 0.01 0.607 0.00 0.01; 0.01 0.714 0.00 0.01; 0.00 0.768
Serum TSH concentration 0.22 0.48; 0.05 0.113 0.01 0.12; 0.09 0.821 0.06 0.20; 0.07 0.375
Serum vitamin B12 concentration 0.01 0.01; 0.01 0.486 0.00 0.01; 0.01 0.949 0.00 0.00; 0.01 0.340
Medial temporal lobe atrophyi 1.13 0.39; 1.87 0.003 0.41 0.11; 0.70 0.007 0.56 0.18; 0.93 0.004
b, coeﬃcient of regression corresponding to a change in the grade of white matter abnormalities; CI, conﬁdence interval; 25OHD, 25-hydrox-
yvitamin D; MMSE, Mini-Mental State Examination; TSH, thyroid-stimulating hormone. aThree diﬀerent regression models were used to pre-
dict consecutively the grade of total, periventricular and deep white matter abnormalities; bdeseasonalized value; cchange per 25 nM of serum
25-hydroxyvitamin D concentration; dantihypertensive, anti-diabetic, lipid-lowering or anti-platelet drugs; ediseases lasting at least 3 months or
running a course with minimal change; fusual gait velocity slower than 100 cm/s; ggraduate studies; hcorrected value; iscore on Scheltens scale
>2 at least on one side. Bold values indicate b signiﬁcant (i.e., P-value < 0.05).
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methodological divergences, both this previous study
and the current study found that older adults with
lower 25OHD status had a higher grade of WMA.
The inverse association between 25OHD status and
WMA grade may have several possible explanations.
First, older individuals with a high burden of WMA
are more likely to have decreased cognitive and func-
tional abilities and to be limited in their mobility [16]
leading to lower intakes of vitamin D and thus to a
greater risk of hypovitaminosis D. For instance, in
multiple sclerosis, impaired mobility has been inver-
sely correlated with reduced sun exposure and (subse-
quently) with lower serum 25OHD concentrations
[35]. However, it is of note that our community-dwell-
ing participants were relatively healthy with high
mean BMI of 25.9  4.0 kg/m2, high mean MMSE
score of 26.9  3.4 and high mean gait velocity of
105.1  23.1 cm/s (Table 1). Moreover, adjustment
for these covariables did not alter the association of
serum 25OHD concentration with WMA (Table 2),
which makes this explanation less likely.
Alternatively, low vitamin D levels may have a role
in precipitating WMA. The pathophysiology of WMA
is not fully elucidated. D-WMA are generally
attributed to cerebral ischaemic small vessel disease
and hypertension, whilst P-WMA probably reﬂect
age-related subcortical brain atrophy [12,13,33]. Inter-
estingly, hypovitaminosis D may be involved in both
of these pathological processes.
Vitamin D has demonstrated numerous links with
vascular health. Speciﬁcally, a potential anti-athero-
sclerotic activity of vitamin D has been highlighted,
and hypovitaminosis D has been associated with a
higher prevalence of peripheral arterial disease [36].
Potential mechanisms for increased vascular disease
risk include increased oxidative stress, lipid peroxida-
tion, glucose intolerance and metabolic syndrome in
the case of hypovitaminosis D [37,38]. Moreover,
hypovitaminosis D appears to be a contributing fac-
tor to hypertension [39], mainly by suppression of
the renin-angiotensin system expression in the juxta-
glomerular apparatus [40]. Deleterious eﬀects of
(a) (b)
(c)
Figure 1 Representative examples of axial T2-weighted FLAIR magnetic resonance images in participants with insuﬃcient (a) and
normal (b) 25-hydroxyvitamin D status. (c) Bar plot representing the mean grade of periventricular white matter abnormalities for par-
ticipants with vitamin D insuﬃciency and normal vitamin D status. Bar graphs indicate mean and 95% conﬁdence interval.
*P = 0.024 for between-group comparison using the two-sided Student t test.
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hypovitaminosis D on vascular brain health have
already been described. A recent SPECT-CT (radio-
nuclide brain Single-Photon Emission Computed
Tomography/Computed Tomography) study in par-
ticipants with Alzheimer’s disease found that serum
25OHD concentration positively correlated with cere-
bral blood ﬂow, those with hypovitaminosis D hav-
ing decreased regional blood ﬂow in the left
precuneus cortex [41]. Consistent with this result, a
meta-analysis showed that in both cross-sectional
and longitudinal studies people with hypovitaminosis
D have more strokes than others [42]. Furthermore,
vitamin D appears not only to prevent cerebral vas-
cular disorder but also to limit its consequences. For
illustration, experiments in rats showed that vitamin
D attenuated cortical infarction induced by cerebral
arterial ligation [11]. Because ischaemic disease is a
plausible determinant of WMA [12,13], increased
brain sensitivity to vascular stress in the case of
hypovitaminosis D may explain part of the hypovita-
minosis-D-related WMA.
Since lower vitamin D status was associated in our
study with P-WMA rather than D-WMA, our results
suggest that the WMA observed in older adults with
hypovitaminosis D may not be fully explained by
cerebral ischaemic small vessel disease but rather by a
loss of subcortical white matter. Experimental evi-
dence precisely supports a role for vitamin D in regu-
lating brain trophism and plasticity. Vitamin D
appears to have a trophic function in the diﬀerentia-
tion and maturation of neurons by controlling the
rate of mitosis and the production and release of neu-
rotrophins. Vitamin D promotes the synthesis of neu-
rotrophic agents such as nerve growth factor, the
glial-cell-line-derived neurotrophic factor and neuro-
trophin 3 [4,5,9]. It also accelerates dendritic growth
in a dose-dependent manner in rodent hippocampal
cell cultures [9]. In vivo observations in animals consis-
tently ﬁnd that vitamin-D-depleted rats present with
enlarged lateral ventricles illustrative of subcortical
atrophy [43]. In the same line, a recent study in
humans conﬁrmed that older adults with hypovita-
minosis D had enlarged lateral ventricles (synonymous
with subcortical parenchymal loss) compared with
those with normal vitamin D status [22]. A previous
report also found that a plasma nutrient pattern rich
in vitamin D was associated with larger whole-brain
volume on MRI [44]. These results strengthen the
hypothesis that WMA observed in older adults with
hypovitaminosis D in our study were probably due to
subcortical atrophy.
The strengths of our study include the distinction
of several locations of WMA (i.e. total WMA, P-
WMA and D-WMA). Additionally, serum vitamin
D concentration was measured using a standardized
and validated automated technique, and both as-
measured and deseasonalized values of serum
25OHD concentrations were used in parallel analy-
ses. Finally, regression models were applied to mea-
sure adjusted associations. Regardless, a number of
limitations also exist. First, the study cohort was
restricted to community-dwelling adults with mem-
ory complaint who might not be representative of
all older adults. Secondly, although it was possible
to control for important characteristics that could
modify the association, residual potential confound-
ers such as serum phosphorus concentration might
still be present. Thirdly, the use of a cross-sectional
design prevents any causal inference. Despite these
limitations, it was possible to demonstrate a 33%
increase in P-WMA associated with hypovitaminosis
D. This new direction of research may oﬀer a pow-
erful mechanism to better understand the patho-
physiology of cognitive disorders in older adults
with lower vitamin D levels, and to act on their
healthcare needs to maintain brain abilities late in
life. Further prospective studies with diﬀerent
patient cohorts are warranted to clarify whether
older adults with hypovitaminosis D are more likely
to experience WMA and whether the correction of
hypovitaminosis D could improve or prevent this
process.
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